Trial Results Demonstrate Diagnostic Performance of Aurora Dedicated Breast MRI System Over Whole-Body Breast MRI

October 2, 2012 — A clinical trial published in the October issue of Radiology demonstrates that Aurora Imaging Technology’s 1.5T dedicated breast MRI (magnetic resonance imaging) system led to better diagnostic performance for all metrics (sensitivity, specificity, negative predictive value [NPV], positive predictive value [PPV] and receiver operating characteristic [ROC] area) than has been historically reported in trials for breast MRI on whole-body MRI scanners. In addition, the low frequency of false positive and false negative findings associated with the dedicated breast MRI system allows for use of breast MRI with low risk of patient harm in both the screening and diagnostic environments. The study was managed by ACR Image Metrix, the American College of Radiology’s clinical research organization.

“The results of this multicenter trial validate what we have suspected for many years, which is, using a dedicated MRI system optimized for breast imaging results in superior diagnostic performance. In addition, we were able to demonstrate consistency of performance across a variety of breast imaging centers, university, community hospital and independent breast centers,” said Steven Harms, M.D., primary investigator for the study.

The study included more than 900 patients and resulted in sensitivity and specificity for the dedicated breast MRI system of 92 percent (92/100) and 88.9 percent (741/834), respectively. For all cases, the NPV was 98.9 percent (741/749), and the NPV for screening cases was 100 percent (326/326). The area under the ROC curve was 94.2 percent. The false positive rate was 93/834 (11 percent) for all cases, but only 16/326 (4.7 percent) for the screening cohort.

Alan Hollingsworth, M.D., medical director, breast surgeon at Mercy Women’s Center at Mercy Health Center, and study investigator added, “False positive rates from previously reported trials using whole-body breast MRI have typically been between 30-50 percent. These studies have led to criticism of breast MRI for its high false positive rates, resulting in unnecessary biopsies, surgical procedures and anxiety for the patient. The dedicated breast MRI system offers a significant improvement in performance. Even within the 93 false positives, 25 (27 percent) were high-risk histologies for which excision is often recommended. This kind of performance should provide breast radiologists and surgeons alike a higher level of diagnostic confidence, and could have significant impact on the role of breast MRI”.

For more information: www.auroramri.com


Related Content

News | Radiology Business

The issue of sustainability in healthcare has gained increasing focus over the past several years. During a 2022 plenary ...

Time May 06, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Oncology Related Products

Nov. 25, 2024 — CancerIQ has launched a new patient acquisition solution for imaging and oncology, CancerIQ Reach.The ...

Time December 03, 2024
arrow
Subscribe Now